Oppenheimer Initiates Coverage On PMV Pharmaceuticals with Perform Rating
Oppenheimer analyst Jeff Jones initiates coverage on PMV Pharmaceuticals (NASDAQ:PMVP) with a Perform rating.
PMV Pharmaceuticals Q2 EPS $(0.29) Misses $(0.27) Estimate
PMV Pharmaceuticals (NASDAQ:PMVP) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.27) by 7.41 percent.
Guggenheim Initiates Coverage On PMV Pharmaceuticals with Buy Rating, Announces Price Target of $56
Guggenheim analyst Charles Zhou initiates coverage on PMV Pharmaceuticals (NASDAQ:PMVP) with a Buy rating and announces Price Target of $56.
HC Wainwright & Co. Initiates Coverage On PMV Pharmaceuticals with Buy Rating, Announces Price Target of $63
HC Wainwright & Co. analyst Robert Burns initiates coverage on PMV Pharmaceuticals (NASDAQ:PMVP) with a Buy rating and announces Price Target of $63.
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
56 Biggest Movers From Yesterday
Gainers
Bridgford Foods Corporation (NASDAQ: BRID) shares surged 46.2% to close at $20.74 on Tuesday.